Losartan Potassium Tablet, Film Coated
Product Images NDC 50090-7795

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-7795). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907795)

FDA Label Image

Losartanpotassiumfigure1 (Losartanpotassiumfigure1)

Losartanpotassiumfigure1 (Losartanpotassiumfigure1)
This text provides information on a clinical trial comparing the effects of Atenolol and Losartan potassium. It shows an adjusted risk reduction of 13% with a p-value of 0.021 for the primary endpoint. The study appears to have been conducted over a period of 66 months, with data points at 6-month intervals.*
FDA Label Image

Losartanpotassiumfigure2 (Losartanpotassiumfigure2)

FDA Label Image

Losartanpotassiumfigure3 (Losartanpotassiumfigure3)

Losartanpotassiumfigure3 (Losartanpotassiumfigure3)
The provided text contains a table showing overall results related to patients' age (<65 years and >65 years), gender (female), diabetes status (yes or no), history of CVD (yes or no), the number of patients in different categories, event rates for Atenolol and Losartan Potassium, as well as hazard ratios for stroke. The text indicates data related to the comparison between Losartan Potassium and Atenolol in terms of stroke outcomes. The table seems to present information related to a medical study or clinical trial.*
FDA Label Image

Losartanpotassiumfigure4 (Losartanpotassiumfigure4)

Losartanpotassiumfigure4 (Losartanpotassiumfigure4)
This is a comparison between Losartan Potassium and Placebo in terms of the percentage of patients experiencing an event. The risk reduction when taking Losartan Potassium is 16.1% compared to Placebo, with a p-value of 0.022.*
FDA Label Image

Losartanpotassiumstructure (Losartanpotassiumstructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.